Glaxo Heart Treatment Darapladib Misses Phase III Primary Endpoint
LONDON (Alliance News) - GlaxoSmithKline PLC said Monday that its Phase III STABILITY study for darapladib in the treatment of patients with chronic coronary heart disease failed to meet its primary endpoint, although it said that the effects of the drug on the reduction of coronary events was of Read More